Another drug, MFGR1877S, a monoclonal antibody targeting FGFR3 has demonstrated promising activity in preclinical models of urothelial carcinoma [15], although failed to work in clinical studies of multiple myeloma treatment. The gene discussed is FGFR3; the disease is urothelial carcinoma.